Project Scope

This project team will create a White Paper with recommendations for adverse event collection instructions, with a focus on Phase 2-4 clinical trials. This White Paper will build upon a paper that outlines results from a survey on current practices, indicating variation that can likely be reduced. Recommendations will be based on the desired end-in-mind, and may or may not be consistent with current practices


Project LeadsEmails
Aimee Basile 
Mary Nilsson 
Wendy Dobson (PHUSE Project Manager)
abasile@surfaceoncology.com
nilsson_mary_e@lilly.com
Wendy@phuse.eu


Resources

Adverse Event Collection & Treatment Emergent Collection: Version 1.0, 27-Aug-2020

White Paper


DeliverablesTimelines




Project MembersCompany
Alec VardyJazzpharma
Cathy BezekAstellas
Elisa YoungSouthernStarResearch
Jeannine HughesBoehringer-Ingelheim
Jun LiSanofi
Kathy TaylorUnither
Kim MusgraveAmgen
Kit HowardCDISC
Lori Van MeterJNJ
Patrick HannonMMSHoldings
Pranab MitraIndustry
Robin WhiteLilly
Tatiana RobersonUnither
William PaloAbbvie